Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic nonsmall cell lung cancer TRAP OLIGO study (WJOG11118L)

Synchronous oligometastatic non-small cell lung cancer (NSCLC) is generally characterised by the limited number of metastases at the time of diagnosis. Several clinical trials have shown that local ablative therapy (LAT) at all sites of the disease might be beneficial for patients with oligometastatic NSCLC.